Form: 10-Q

Quarterly report pursuant to Section 13 or 15(d)

May 17, 1999

Documents

STATEMENT RE: COMPUTATION OF EARNINGS PER SHARE

Published on May 17, 1999


EXHIBIT 11

CYTOCLONAL PHARMACEUTICS INC.


COMPUTATION OF NET (LOSS) PER COMMON SHARE
(unaudited)




THREE MONTHS
ENDED MARCH 31,
1999 1998
------------ ------------


Net (loss) $ (1,085,000) $ (790,000)

Add cumulative preferred dividend (49,000) (61,000)
------------ ------------

NET (LOSS) USED FOR COMPUTATION $ (1,134,000) $ (851,000)

Weighted average number of common shares outstanding
outstanding - basic and diluted loss per share 10,268,000 8,840,000
------------ ------------

Basic and diluted loss per common share $ (0.11) $ (0.10)